Covid-19: Pharma firms reduce price of Remdesivir after government intervention

The price of Remdesivir Injection has been reduced following government’s intervention. National Pharmaceutical Pricing Authority said, major Pharma companies have announced voluntary price cuts for Remdesivir Injections after Centre's intervention to ensure it's affordable availability.

Cadila Healthcare's Remdac will now cost 899 rupees instead of 2 thousand 8 hundred rupees.

Syngene International's RemWin will now cost 2 thousand 450 rupees instead of 3 thousand 950 rupees. Dr Reddy's Redyx will be available at 2 thousand 700 rupees instead of 5 thousand 400 rupees. Cipla's Cipremi will cost 3 thousand rupees instead of 4 thousand rupees.

Mylan Pharmaceutical's Desrem will be available at 3 thousand 400 rupees instead of 4 thousand 800 rupees. Jubilant Generic's Jubi-R will now cost 3 thousand 400 rupees instead of 4 thousand 700 rupees. Hetero Healthcare's Covifor will be available at 3 thousand 490 rupees instead of 5 thousand 400 rupees.

"On the Intervention of the Government the major manufacturers/markers of 'RemdesIvir Injection' have reported voluntary reduction in Maximum Retail (MRP)," the Department of Pharmaceuticals National Pharmaceutical Pricing Authority stated.